Effect of a Mycobacterium vaccae derivative on paediatric atopic dermatitis: A randomized, controlled trial

Clinical and Experimental Dermatology

Volumn 34, Issue 7, 2009, Pages 770-775

  Brothers, S ^a   Asher, M I ^a   Jaksic, M ^a   Stewart, A W ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOBACTERIUM VACCAE DERIVATIVE; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM VACCAE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM;

ADOLESCENT; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE; MYCOBACTERIUM; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VACCINES, INACTIVATED;

EID: 70349495659     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2008.03153.x     Document Type: Article

References (25)

1. Williams H, Robertson C, Stewart A et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999 103 : 125 138.
2. Asher MI, Montefort S, Bjorksten B et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 2006 368 : 733 743.
3. Irvine AD, McLean WH. Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. J Invest Dermatol 2006 126 : 1200 1202.
4. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989 299 : 1259 1260.
5. von Mutius E, Pearce N, Beasley R et al. International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis, and eczema. Thorax 2000 55 : 449 453.
6. Flohr C, Pascoe D, Williams HC. Atopic dermatitis and the 'hygiene hypothesis': too clean to be true? Br J Dermatol 2005 152 : 202 216.
7. Zuany-Amorim C, Manlius C, Trifilieff A et al. Long-term protective and antigen-specific effect of heat-killed Mycobacterium vaccae in a murine model of allergic pulmonary inflammation. J Immunol 2002 169 : 1492 1499.
8. Zuany-Amorim C, Sawicka E, Manlius C et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med 2002 8 : 625 629.
9. Shirtcliffe PM, Easthope SE, Cheng S et al. The effect of delipidated deglycolipidated (DDMV) and heat-killed Mycobacterium vaccae in asthma. Am J Resp Crit Care Med 2001 163 : 1410 1414.
10. Hopkin JM, Shaldon S, Ferry B et al. Mycobacterial immunisation in grass pollen asthma and rhinitis. Thorax 1998 53 (Suppl. 4 S16A.
11. Arkwright PD, David TJ. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol 2001 107 : 531 534.
12. Arkwright PD, David TJ. Effect of Mycobacterium vaccae on atopic dermatitis in children of different ages. Br J Dermatol 2003 149 : 1029 1034.
13. Williams HC, Burney PG, Pembroke AC et al. Inventors; Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. UK Diagnostic Criteria for Atopic Dermatitis Working Party. Br J Dermatol 1996 135 : 12 17.
14. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol 1989 144 (Suppl. 13 14.
15. Berth-Jones J. Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 1996 135 (Suppl. 48 25 30.
16. Sowden JM, Berth-Jones J, Ross JS et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991 338 : 137 140.
17. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995 132 : 942 949.
18. British Medical Association Royal Pharmaceutical Society of Great Britain. British National Formulary, no 46. London : British Medical Association and Royal Pharmaceutical Society of Great Britain, 2003.
19. Rosenfeldt V, Benfeldt E, Nielsen SD et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003 111 : 389 395.
20. Flohr C, Johansson SG, Wahlgren CF, Williams H. How atopic is atopic dermatitis? J Allergy Clin Immunol 2004 114 : 150 158.
21. Berth-Jones J, Arkwright PD, Marasovic D et al. Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Clin Exp Allergy 2006 36 : 1115 1121.
22. Arkwright PD, Fujisawa C, Tanaka A et al. Mycobacterium vaccae reduces scratching behaviour but not the rash in NC mice with eczema: a randomized, blinded, placebo-controlled trial. J Invest Dermatol 2005 124 : 140 143.
23. Umetsu DT, Akbari O, Dekruyff RH. Regulatory T cells control the development of allergic disease and asthma. J Allergy Clin Immunol 2003 112 : 480 487. (Pubitemid 37108548)
24. von Hertzen L, Haahtela T. Disconnection of man and the soil: reason for the asthma and atopy epidemic? J Allergy Clin Immunol 2006 117 : 334 344.
25. Hunt JR, Martinelli R, Adams VC. Intragastric administration of Mycobacterium vaccae inhibits severe pulmonary allergic inflammation in a mouse model. Clin Exp Allergy 2005 35 : 685 690.